| __timestamp | Axsome Therapeutics, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 104381000 |
| Thursday, January 1, 2015 | 6776987 | 100171000 |
| Friday, January 1, 2016 | 21199860 | 102726000 |
| Sunday, January 1, 2017 | 19957616 | 96171000 |
| Monday, January 1, 2018 | 23495055 | 66449000 |
| Tuesday, January 1, 2019 | 53647067 | 42672000 |
| Wednesday, January 1, 2020 | 70244579 | 42534000 |
| Friday, January 1, 2021 | 58060725 | 53311000 |
| Saturday, January 1, 2022 | 57947447 | 82258000 |
| Sunday, January 1, 2023 | 97944000 | 118011000 |
| Monday, January 1, 2024 | 187077000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) investments are crucial for driving innovation and maintaining a competitive edge. Over the past decade, Axsome Therapeutics, Inc. and Celldex Therapeutics, Inc. have demonstrated contrasting strategies in their R&D expenditures.
From 2014 to 2023, Celldex consistently outspent Axsome, with its R&D expenses peaking in 2023 at approximately 118 million USD, a 13% increase from the previous year. In contrast, Axsome's R&D spending showed a remarkable growth trajectory, culminating in a 98 million USD investment in 2023, marking a staggering 128% increase from its 2014 expenditure.
This data highlights the dynamic nature of R&D investments in the biotech sector, where strategic financial commitments can significantly influence a company's innovation pipeline and market position.
Research and Development: Comparing Key Metrics for Johnson & Johnson and Celldex Therapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
R&D Insights: How Gilead Sciences, Inc. and Axsome Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Zoetis Inc. vs Axsome Therapeutics, Inc.
R&D Spending Showdown: BeiGene, Ltd. vs Celldex Therapeutics, Inc.
Research and Development Investment: Viatris Inc. vs Axsome Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Blueprint Medicines Corporation vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Grifols, S.A. and Celldex Therapeutics, Inc.
R&D Spending Showdown: Corcept Therapeutics Incorporated vs Celldex Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.